Related Experiment Video

Updated: Jun 23, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Challenging issues in molecular-targeted therapy

Zoheir Ezziane1

  • 1Applied Science and Technology, Higher Colleges of Technology, Al Ain, United Arab Emirates.

Therapeutics and Clinical Risk Management
|May 14, 2009
PubMed

Insights

This study proposes a novel three-drug anticancer compound. It explores challenges in developing multidrug therapies for targeted cancer treatment, focusing on chemotherapy and histone deacetylase inhibitors.

Area of Science:

  • Oncology and Pharmacology
  • Molecular Biology and Genetics

Background:

  • Chemotherapeutic drugs induce cancer cell death via DNA damage and cytoskeleton disruption.
  • Histone deacetylase (HDAC) inhibitors exert antitumor effects by modulating gene expression and chromatin structure, impacting cell cycle and survival.
  • Developing effective multidrug anticancer therapies remains a significant challenge in oncology.

Purpose of the Study:

  • To propose a novel three-drug compound for anticancer therapy.
  • To discuss the complexities and challenges associated with designing effective multidrug anticancer agents.
  • To explore the potential of these compounds in advancing molecular-targeted cancer therapies.

Main Methods:

  • Literature review and conceptual design of a three-drug compound.
  • Analysis of mechanisms of action for chemotherapy and HDAC inhibitors.
  • Discussion of challenges in multidrug compound design and formulation.

Main Results:

  • A conceptual framework for a three-drug anticancer compound is presented.
  • Key challenges in developing multidrug therapies, including drug interactions and delivery, are identified.
  • The potential for synergistic effects and improved therapeutic outcomes is highlighted.

Conclusions:

  • The proposed three-drug compound offers a potential strategy for enhanced anticancer efficacy.
  • Addressing design challenges is crucial for the successful clinical translation of multidrug therapies.
  • This approach may pave the way for more personalized and molecular-targeted cancer treatments.

More Related Videos

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...